Revenue
2020
2021
2022
2023
2024
2025
TScan Therapeutics, Inc. (TCRX)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $10.3M | $2.8M | $21.0M | $13.5M | $10.1M | $1.1M |
| Research & development | $114.2M | $107.3M | $88.2M | $59.8M | $45.0M | $20.6M |
| Operating expenses | $146.1M | $137.6M | $114.5M | $80.2M | $58.8M | $27.3M |
| Operating income | −$135.8M | −$134.8M | −$93.5M | −$66.6M | −$48.6M | −$26.2M |
| EBITDAderived | −$132.9M | −$130.7M | −$88.1M | −$61.5M | −$45.3M | −$25.0M |
| Net income | −$129.8M | −$127.5M | −$89.2M | −$66.2M | −$48.6M | −$26.1M |
| Basic EPSper diluted share | -$1.00 | -$1.14 | -$1.36 | -$2.75 | -$4.17 | -$28.52 |
| Diluted EPSper diluted share | -$1.00 | -$1.14 | -$1.36 | -$2.75 | -$4.17 | -$28.52 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Dec 23, 2025Form 4 | Lynx1 Capital Management LP +1TenPercentOwner | BuyCommon Stock · indirect | 6.2K | $0.90 | $5.6K | 8.02M |
| Dec 22, 2025Form 4 | Lynx1 Capital Management LP +1TenPercentOwner | BuyCommon Stock · indirect | 75.5K | $0.90 | $68.0K | 8.01M |
| Dec 19, 2025Form 4 | Lynx1 Capital Management LP +1TenPercentOwner | BuyCommon stock, $0.0001 par value per share ("Common Stock") · indirect | 80.1K | $0.90 | $72.1K | 7.94M |
| May 20, 2025Form 4 | Lynx1 Capital Management LP +1TenPercentOwner | BuyCommon Stock · indirect | 1.20M | $1.20 | $1.44M | 7.95M |
| May 19, 2025Form 4 | Lynx1 Capital Management LP +1TenPercentOwner | BuyCommon stock, $0.0001 par value per share ("Common Stock") · indirect | 1.39M | $1.20 | $1.67M | 6.75M |